NCT02881216已完成不适用
Procedural Advantages of a Novel Drug-Eluting Coronary Stent With Ultra-Thin Struts and Bioabsorbable Abluminal Polymer Coating in an All-Comers Registry
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 814
- 主要终点
- In-hospital major cardiac adverse events
研究概览
简要总结
This study sought to compare procedural performance of a new coronary stent generation, that is already available in Germany, with hitherto established current drug-eluting stents.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •CAD for PCI, consecutive patients
排除标准
- •Age under 18
- •Bare Metal Stents or Scaffolds
结局指标
主要结局
In-hospital major cardiac adverse events
时间窗: One week post-procedure
In-hospital major cardiac adverse events were collected up to one week after procedure throughout the in-patients stay
次要结局
未报告次要终点
研究者
Haitham Abu Sharar
Principal Investigator
University Hospital Heidelberg
相似试验
Unknown
不适用
Xience Versus Synergy in Left Main PCICoronary Artery DiseaseNCT02303717NHS National Waiting Times Centre Board818
已完成
不适用
New-DES vs BMS in SVG -1 Year OutcomesCoronary Artery DiseaseNCT04338308Medical University of Silesia792
已完成
4 期
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) TrialNon-ST Segment Elevation Myocardial InfarctionUnstable AnginaStable AnginaNCT02601157Seoul National University Hospital2,173
Unknown
2 期
Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary StentCoronary Artery DiseaseMyocardial IschemiaNCT02189499Amaranth Medical Inc.42
已完成
不适用
Optimal Treatment for Coronary Drug Eluting Stent In-stent RestenosisCoronary Stent RestenosisNCT04862052Semmelweis University Heart and Vascular Center108